Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol (vol 10, pg e46, 2023)-MedSci.cn

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol (vol 10, pg e46, 2023)

Watts, JM; Baer, MR; Yang, J

LANCET HAEMATOLOGY, 2023; 10 (1): E9

科室
- - 订阅+
  - 更多科室
工具
服务